MiNK Therapeutics (NASDAQ:INKT) Issues Quarterly Earnings Results

MiNK Therapeutics (NASDAQ:INKT) released its earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02), Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK advanced agenT-797 into a randomized Phase II ARDS study, with enrollment continuing in Ukraine and U.S. sites expected to begin enrolling in September. The company expects preliminary randomized data in the first half of 2027 and is preparing to discuss a potential seamless Phase III design with the FDA.
• Initial observations from two treated patients showed survival without fever at day 28, improved oxygenation, ARDS resolution, spontaneous breathing, vasopressor liberation, infection control, and no major treatment-related serious adverse events. However, management emphasized that the data are early, non-comparative, and based on a small run-in cohort.
• MiNK launched its first international paid named-patient access program in Brazil, generating physician-directed access and payments while building cross-border logistics and regulatory infrastructure. The company said additional patients were treated after quarter-end and that further financial details are expected with its third-quarter update.
• MiNK ended the quarter with $8.8 million in cash, down from $9.5 million at the end of the first quarter, while quarterly operating cash use increased to $2.1 million as the Phase II trial was operationalized. The company continues to report losses and did not provide explicit cash-runway guidance.

MiNK Therapeutics Trading Down 3.2%

Shares of NASDAQ INKT traded down $0.36 during midday trading on Thursday, reaching $11.00. 8,592 shares of the stock were exchanged, compared to its average volume of 9,561. MiNK Therapeutics has a 12 month low of $8.48 and a 12 month high of $18.17. The business has a 50-day simple moving average of $11.34 and a two-hundred day simple moving average of $11.23.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC raised its holdings in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the Securities and Exchange Commission. 2.87% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on INKT. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Zacks Research upgraded shares of MiNK Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a research note on Monday, May 18th. Finally, Weiss Ratings upgraded shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell?to?cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor?associated macrophages and boost T cell–mediated tumor clearance.